What the FDA labels say about taking them together
Amiodarone and nateglinide
Nateglinide's FDA label of February 24, 2025 names amiodarone in its drug interactions section; the amiodarone labels PlainMeds reads (2) do not name nateglinide. The nateglinide label: “Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective …”
Check it at the source: the amiodarone FDA label on DailyMed (effective December 9, 2025, Chartwell RX, LLC); the nateglinide FDA label on DailyMed (effective February 24, 2025, Strides Pharma Science Limited).
What does the amiodarone label say about nateglinide?
Amiodarone's label (effective December 9, 2025) and its 1 other brand-application label do not name nateglinide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Amiodarone Hydrochloride), Chartwell RX, LLC, effective December 9, 2025 (SPL set 5520f11d-968d-4f4f-bf57-d14369c0d746), via openFDA; the full label on DailyMed
What does the nateglinide label say about amiodarone?
Nateglinide label, drug interactionsDrugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs.
Source: FDA drug label (Nateglinide), Strides Pharma Science Limited, effective February 24, 2025 (SPL set 0ccf9b07-3c21-482d-abeb-a06ceb482c7b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amiodarone | Nateglinide | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.122 per tablet 200 mg tablet | $0.179 per tablet 60 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once